GLP1R and Stroke: Meanwhile, GLP-1 RAs, such as semaglutide and efpeglenatide, excelled in reducing MACE, including nonfatal myocardial infarction and stroke, as demonstrated in the AMPLITUDE-O [9] and FLOW [10] trials.